Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

537
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

743
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

616
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
616

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transformer networks enable fast and robust dictionary generation for multiparametric cardiac mapping with variable timing.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

Low-dose levosimendan infusions in advanced heart failure: efficacy, safety, and factors associated with outcomes.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Prognostic impact of systolic blood pressure trajectory among patients hospitalised in an acute heart failure setting: insights from a real-world multinational cohort.

Swiss medical weekly·2026
Same author

Navigator-gated free-breathing joint T<sub>1</sub>-T<sub>2</sub> mapping of the kidney.

Magma (New York, N.Y.)·2026
Same author

Cardiac function assessment with deep-learning-based automatic segmentation of free-running four-dimensional whole-heart cardiovascular magnetic resonance.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2025
Same author

Prognostic Impact of Cardiovascular-Kidney-Metabolic Overlap Among Patients With Acute Heart Failure: Insights From a Real-World Multinational Cohort.

Journal of the American Heart Association·2025

Related Experiment Video

Updated: Mar 24, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Mechanical circulatory support for destination therapy.

Piergiorgio Tozzi1, Roger Hullin2

  • 1Service de chirurgie cardio-vasculaire, CHUV, Lausanne, Switzerland.

Swiss Medical Weekly
|March 6, 2016
PubMed
Summary
This summary is machine-generated.

Destination therapy using mechanical circulatory support significantly improves quality of life and survival for advanced heart failure patients ineligible for transplant. Newer devices offer improved durability and reduced complications, making it a viable treatment option.

More Related Videos

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K

Related Experiment Videos

Last Updated: Mar 24, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K

Area of Science:

  • Cardiology
  • Medical Devices
  • Surgical Innovation

Background:

  • Chronic heart failure patients ineligible for heart transplant often have limited life expectancy.
  • Mechanical circulatory support (MCS) can restore cardiac output and improve organ perfusion.
  • Destination therapy (DT) is a specific application of MCS for long-term management.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of destination therapy (DT) with modern mechanical circulatory support devices.
  • To assess the impact of DT on patient survival and quality of life compared to medical management.
  • To review advancements in device technology, implantation techniques, and patient selection for DT.

Main Methods:

  • Review of contemporary continuous flow, rotary/axial blood pumps (e.g., HeartMate II, HeartWare HVAD).
  • Analysis of minimally invasive implantation techniques on a beating heart.
  • Evaluation of patient selection criteria, including inclusion/exclusion criteria and optimal timing.
  • Assessment of survival rates, complication incidence (bleeding, infection), and quality of life improvements.

Main Results:

  • Modern MCS devices demonstrate improved durability with near 10-year freedom from mechanical failure.
  • Actuarial survival rates for selected DT patients are 75% at 1 year and 62% at 2 years.
  • Significant improvements in quality of life are observed compared to medical management alone.
  • Complications like bleeding and infections are less frequent and better managed than with older devices.

Conclusions:

  • Destination therapy with advanced mechanical circulatory support is an effective and increasingly cost-effective option for eligible heart failure patients.
  • Current MCS technology offers encouraging survival rates and substantial quality of life benefits.
  • Ongoing refinement of patient selection and implantation techniques will further enhance DT outcomes.